tfmp-y4

**TFMP-Y4** is a novel small-molecule polypeptide developed for potential use in targeted internal irradiation therapy for cancer, specifically hepatocellular carcinoma (HCC). It is derived from modified versions of the caerin 1.1 peptide, originally isolated from the glandular secretions of the Australian tree frog. Unlike caerin 1.1, TFMP-Y4 itself does not have intrinsic antiproliferative effects against tumor or normal cells. However, when labeled with iodine-131 (¹³¹I), forming ¹³¹I-TFMP-Y4, it acts as a tumor-targeting radiopharmaceutical. The primary mechanism involves the selective uptake and retention of the radiolabeled peptide by tumor cells, leading to targeted irradiation and inhibition of tumor growth. This approach is designed to minimize adverse effects on normal tissues, as TFMP-Y4 lacks the direct cytotoxic activity seen with caerin 1.1. Preclinical studies indicate that ¹³¹I-TFMP-Y4 can significantly inhibit the growth of HepG2 (liver cancer) cells both in vitro and in vivo, but is less potent than ¹³¹I-caerin 1.1, which combines both targeted radiation and direct peptide-mediated cytotoxicity. The development of TFMP-Y4 reflects an effort to reduce treatment-related adverse events by separating the cytotoxic and radiation components of therapy[1][3].